Nitric oxide treatment

Due to the recognized biological role of nitric oxide (NO) donating derivatives and of selective inhibitors of specific human carbonic anhydrase isoforms (CA, EC 4.2.1.1), promising compounds having an aromatic/heterocyclic primary sulfonamide and functionalized with NO-releasing moieties have been designed. These bifunctional agents have been tested in vitro and in vivo to assess their dual pharmacological activity. According to the encouraging results they could be proposed for the treatment of angle-open glaucoma, cancer regression and osteoporosis, in which both NO and CA activities are involved.

MDPI and ACS Style

Carradori, S.; Mollica, A.; De Monte, C.; Granese, A.; Supuran, C.T. Nitric Oxide Donors and Selective Carbonic Anhydrase Inhibitors: A Dual Pharmacological Approach for the Treatment of Glaucoma, Cancer and Osteoporosis. Molecules 2015, 20, 5667-5679.

AMA Style

Carradori S, Mollica A, De Monte C, Granese A, Supuran CT. Nitric Oxide Donors and Selective Carbonic Anhydrase Inhibitors: A Dual Pharmacological Approach for the Treatment of Glaucoma, Cancer and Osteoporosis. Molecules. 2015; 20(4):5667-5679.

Carradori, Simone; Mollica, Adriano; De Monte, Celeste; Granese, Arianna; Supuran, Claudiu T. 2015. "Nitric Oxide Donors and Selective Carbonic Anhydrase Inhibitors: A Dual Pharmacological Approach for the Treatment of Glaucoma, Cancer and Osteoporosis." Molecules 20, no. 4: 5667-5679.

Notes: Multiple requests from the same IP address are counted as one view.

No